First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Almirall: the story is balanced — Clinical trial results and regulatory approvals for pipeline candidates - particularly in high-value dermatology…
★ Analysts see FY2026 revenue reaching $1.2B — +10.8% growth in a single year.
What Moves the Stock
1Clinical trial results and regulatory approvals for pipeline candidates - particularly in high-value dermatology indications like atopic dermatitis and psoriasis
2Quarterly prescription volume trends for key products (Ilumetri, Skilarence) in core European markets - Germany, Spain, Italy, France
3Geographic expansion progress - particularly penetration in US market through partnerships or direct entry
4Pipeline development milestones and licensing deal announcements for novel dermatology assets
5Healthcare reimbursement policy changes in major European markets affecting specialty drug pricing
6Proprietary dermatology products (estimated 60-65% of revenue) - branded prescription treatments for psoriasis, atopic dermatitis, acne, and other skin conditions
7Generic dermatology portfolio (estimated 25-30%) - off-patent topical treatments and established brands in European markets
8Medical aesthetics and OTC products (estimated 10-15%) - consumer-facing skincare and aesthetic dermatology solutions
growth - The 70.4% one-year return and 10.2% revenue growth attract growth-oriented investors betting on successful product launches…
Rising interest rates have moderate negative impact through higher discount rates applied to long-duration pharma cash flows…
Watch on earnings: EUR/USD exchange rate - impacts revenue translation and competitiveness given European revenue concentration, European pharmaceutical price index trends - signals reimbursement environment for specialty drugs, Dermatology prescription volume trends in Germany, Spain, Italy - core markets for revenue growth.
One Sentence Summary:
Almirall: the story is balanced — clinical trial results and regulatory approvals for pipeline candidates - particularly in high-value dermatology indications like atopic.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.